Actor
MaxiVAX
Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.
Specialties
Primary Therapeutic Areas
0. COVID-19
1.0 Therapeutic & Diagnostic
1.00 Antibodies & Anti-infectious
1.02 Cell Therapy & Stem Cell
1.05 Gene Therapy
1.10 Small Molecules
1.11 Vaccine
Business model
1. Entreprise
1.2 Scale-Up
Organization Type
Private Company
Visit website
Domains
Immunology & Allergy, Oncology, Vaccine
Main sector
Biotech
Contact
Avenue de Sécheron 15
1202 Geneva / GE
+41 22 552 26 13